

RESEARCH ARTICLE

HLA-DRB1 and DQB1 alleles in Japanese type 1 autoimmune hepatitis: The predisposing role of the DR4/DR8 heterozygous genotype

Shomi Oka^{1,2}, Hiroshi Furukawa^{1,2*}, Michio Yasunami^{3,4}, Aya Kawasaki¹, Hitomi Nakamura⁴, Minoru Nakamura^{5,6,7}, Atsumasa Komori^{6,7}, Seigo Abiru⁷, Shinya Nagaoka⁷, Satoru Hashimoto⁷, Atsushi Naganuma⁷, Noriaki Naeshiro⁷, Kaname Yoshizawa⁷, Haruhiro Yamashita⁷, Keisuke Ario⁷, Hajime Ohta⁷, Hironori Sakai⁷, Iwao Yabuuchi⁷, Atsushi Takahashi⁸, Kazumichi Abe⁸, Hiroshi Yatsuhashi^{6,7}, Shigeto Tohma², Hiromasa Ohira⁸, Naoyuki Tsuchiya¹, Kiyoshi Migita^{6,7,8}

1 Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Japan, **2** Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, 18–1 Sakuradai, Minami-ku, Sagamihara, Japan, **3** Department of Medical Genomics, Life Science Institute, Saga-ken Medical Centre Koseikan, 400 Kasemachi-Nakabaru, Saga, Japan, **4** Department of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, Japan, **5** Department of Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-12-4 Sakamoto, Nagasaki, Japan, **6** Clinical Research Center, National Hospital Organization Nagasaki Medical Center, 2-1001-1 Kubara, Omura, Japan, **7** NHO-AIH study group, National Hospital Organization Nagasaki Medical Center, 2-1001-1 Kubara, Omura, Japan, **8** Department of Gastroenterology and Rheumatology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, Japan

☯ These authors contributed equally to this work.

* furukawa-tyk@umin.org



OPEN ACCESS

Citation: Oka S, Furukawa H, Yasunami M, Kawasaki A, Nakamura H, Nakamura M, et al. (2017) *HLA-DRB1* and *DQB1* alleles in Japanese type 1 autoimmune hepatitis: The predisposing role of the DR4/DR8 heterozygous genotype. PLoS ONE 12(10): e0187325. <https://doi.org/10.1371/journal.pone.0187325>

Editor: Valli De Re, Istituto di Ricovero e Cura a Carattere Scientifico Centro di Riferimento Oncologico della Basilicata, ITALY

Received: July 31, 2017

Accepted: October 17, 2017

Published: October 31, 2017

Copyright: © 2017 Oka et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: The work was supported by Grants-in-Aid for Clinical Research from National Hospital Organization and Grants-in-Aid for Scientific Research (B) (26293076) from the Japan Society for the Promotion of Science. The funders had no

Abstract

Objective

Autoimmune hepatitis (AIH) is a chronic progressive liver disease. AIH is composed predominantly of type 1 in Japanese populations. The genetic and environmental factors are associated with the pathogenesis of AIH. *HLA-DRB1*03:01* and **04:01* are associated with type 1 AIH in European and **04:05* in Japanese populations. Here, we conducted an *HLA* association study in order to find *HLA* alleles or haplotypes predisposing or protective for Japanese AIH.

Methods

HLA-DRB1 and *DQB1* genotyping of 360 type 1 AIH patients and 1026 healthy controls was performed.

Results

The predisposing association of *DRB1*04:01* ($P = 0.0006$, corrected $P[PC] = 0.0193$, odds ratio [OR] 2.97, 95% confidence interval [CI] 1.62–5.43), *DRB1*04:05* ($P = 1.89 \times 10^{-21}$, $PC = 5.86 \times 10^{-20}$, OR 3.41, 95% CI 2.65–4.38), and *DQB1*04:01* ($P = 4.66 \times 10^{-18}$, $PC = 6.99 \times 10^{-17}$, OR 3.89, 95% CI 2.84–5.33) and the protective association of *DRB1*13:02* ($P =$

role in study design, data collection and analysis, decision to publish, or preparing the manuscript.

Competing interests: ST was supported by research grants from pharmaceutical companies: AbbVie GK., Ayumi Pharmaceutical Corporation, Chugai Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Company Limited. ST received honoraria from AbbVie GK., Astellas Pharma Inc., Ayumi Pharmaceutical Corporation, Mitsubishi Tanabe Pharma Corporation, Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc, Takeda Pharmaceutical Company Limited. The other authors declare no financial or commercial conflict of interest. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

= 0.0003, $P_c = 0.0080$, OR 0.48, 95% CI 0.32–0.72) with Japanese type 1 AIH were observed. An association of the DR4/DR8 heterozygous genotype with Japanese AIH was identified for the first time ($P = 3.12 \times 10^{-9}$, OR 3.52, 95% CI 2.34–5.29). Susceptible diploypes were *DRB1*04:05-DQB1*04:01/DRB1*08:02-DQB1*03:02* ($P = 0.0004$, OR 24.77, 95% CI 1.45–424.31) and *DRB1*04:05-DQB1*04:01/DRB1*08:03-DQB1*06:01* ($P = 1.18 \times 10^{-6}$, OR 10.64, 95% CI 3.19–35.46). Serum levels of Immunoglobulin G and Immunoglobulin M, International Autoimmune Hepatitis Group score, positive rate of anti-smooth muscle antibodies, and the rate of definite AIH were higher in AIH patients with *DRB1*04:05* than without.

Conclusions

The important roles of specific combinations of *DRB1* and *DQB1* alleles or haplotypes in the pathogenesis of type 1 AIH were suggested. The association of DR4/DR8 heterozygous genotype suggested the pathologic importance of trans-complementing DQ α - β heterodimer molecules encoded by *DQA1* allele of one haplotype and the *DQB1* allele of the other haplotype, as it was proposed in the HLA association studies of Type 1 diabetes.

Introduction

Autoimmune hepatitis (AIH) is a very rare chronic progressive liver disease with autoimmune features [1,2,3]. Type 1 AIH is characterized by the presence of serum anti-nuclear antibodies (ANA) or anti-smooth muscle antibodies (ASMA) and type 2 AIH by type 1 liver-kidney microsomal antibodies. AIH is composed predominantly of type 1 in Japanese populations. Although the disease etiology is uncertain, it is considered that the genetic and environmental factors are associated with the pathogenesis of AIH. Many studies including a recent genome-wide association study [4] showed the genetic association of AIH with genes located within human leukocyte antigen (*HLA*) region. *HLA-DRB1*03:01* and **04:01* are associated with AIH in European populations [5]; **04:05* is associated in Japanese and Korean populations [6,7,8,9]. In addition, several studies have shown that *DRB1*04:04*, **04:05*, and **13:01* are associated with AIH in Latin America [10,11,12,13]. *DRB1*08* alleles are also reported to be associated with AIH in Indian and Iranian, but not in Pakistani populations [14,15,16]. On the other hands, *DRB1*15:01* is protective for the susceptibility of AIH in European and Japanese populations [5,6]. *DRB1*13:02*, which differ by one amino acid residue from *DRB1*13:01*, is protectively associated with AIH in Latin America [11,13,17] and in Japan [8].

It was reported in the genome-wide association study that *HLA* is the sole strong genetic factor for the susceptibility of type 1 AIH [4]. The *HLA* region was scanned and the most important loci for the susceptibility of type 1 AIH was reported to be *DRB1* [18]. It was suggested that no other genes in the *HLA* region are associated with type 1 AIH. However, *DRB1* is in strong linkage disequilibrium with *DQB1* and it is difficult to differentiate the role of *DRB1* and *DQB1* in the pathogenesis of type 1 AIH. Although *HLA* alleles are known to confer the risk for various autoimmune diseases, the precise mechanisms have not sufficiently been revealed. The risk alleles are different in these autoimmune diseases [19]. It was considered that different auto-antigens are presented by different disease-specific risk alleles; the presented auto-antigens are restricted by *HLA* alleles and are influenced by non-*HLA* genes, environmental factors, or precipitating events. The complex of auto-antigens and risk alleles

stimulate self-reactive T cells, resulting in the eliciting of diseases [20]. In this study, we conducted an HLA association study in order to search HLA alleles or haplotypes predisposing or protective for Japanese AIH.

Materials and methods

Patients and healthy controls

Three hundred sixty type 1 AIH patients were enrolled from the register of Japanese National Hospital Organization Liver Registry [21]. The AIH patients without any other types of liver diseases satisfied the criteria of International Autoimmune Hepatitis Group (IAIHG) for diagnosis of type I AIH [22]. The healthy controls ($n = 1026$; mean age \pm SD, 37.7 ± 11.7 years, 303 male [29.8%]) were recruited at Sagamihara Hospital, the University of Tokyo, Teikyo University, and Kanazawa University [23,24] or by the Pharma SNP Consortium (Tokyo, Japan) [25]. All the patients and the healthy individuals were native Japanese living in Japan. The study was reviewed and approved by University of Tsukuba Research Ethics Committee, Nagasaki University Research Ethics Committee, and the NHO central Institutional Review Board. Informed consents in writing were obtained from all the participants. The study was performed in accordance with the principles expressed in the Declaration of Helsinki.

Genotyping methods

Genotyping of *HLA-DRB1* and *DQB1* was conducted by the polymerase chain reaction with sequence-specific oligonucleotide probes (WAKFlow HLA typing kits, Wakunaga, Hiroshima, Japan), using the Bio-Plex 200 system (Bio-Rad, Hercules, CA). HLA-DR4 serological group includes *DRB1*04:01*, **04:03*, **04:04*, **04:05*, **04:06*, **04:07*, and **04:10*. DR6 is composed of *DRB1*13:01*, **13:02*, **14:03*, **14:04*, **14:05*, **14:06*, **14:07*, **14:29*, and **14:54*. DR8 consists of *DRB1*08:02*, **08:03*, and **08:09*. Genotyping results of *HLA-DRB1* and *DQB1* for some of the AIH patients were previously reported [8]. Genotyping results of *DRB1* for all of the healthy controls ($n = 1026$) were previously reported [8,23,24]. Reported genotyping results of *DQB1* for some of the healthy controls ($n = 413$; mean age \pm SD, 39.3 ± 11.0 years, 61 male [14.8%]) were used for the analyses on *DQB1* allele, *DQB1* genotype, *DRB1-DQB1* haplotype, *DRB1-DQB1* diplotype, and acid residues in the DQ β chain [24]. *DRB1-DQB1* haplotypes were elucidated by direct counting, because *DRB1* is in strong linkage disequilibrium with *DQB1*.

Statistical analysis

Differences of AIH characteristics were analyzed by Mann-Whitney's U test or Fisher's exact test using 2x2 contingency tables. Association of allele carrier frequencies, haplotype carrier frequencies, or amino acid residue carrier frequencies was analyzed by Fisher's exact test using 2x2 contingency tables under the dominant model. Differences of genotype frequencies or diplotype (the specific combination of *DRB1-DQB1* haplotypes) frequencies were analyzed by Fisher's exact test using 2x2 contingency tables. Adjustment for multiple comparisons was conducted with Bonferroni method; corrected P (P_c) values were calculated by multiplying the P value by the number of alleles or amino acid residues tested.

Results

Clinical features of type I AIH patients

Characteristics of the type I AIH patients are shown in Table 1. Among 360 AIH patients, 314 (87.2%) were positive for ANA, 118 (38.6%) were positive for ASMA. Of overall AIH, 227 (63.1%) were definite AIH.

Table 1. Characteristics of type I AIH patients.

	AIH
Number	360
Male, n (%)	43 (11.9%)
Mean age, years (SD)	62.9 (±13.5)
Age at onset, years (SD)	59.1 (±13.5)
Albumin (g/dl) (SD)	3.8 (±0.6)
Total bilirubin (mg/dl) (SD)	3.7 (±4.9)
AST(IU/L) (SD)	469.7 (±546.2)
ALT(IU/L) (SD)	507.5 (±510.1)
ALP(IU/L) (SD)	465.2 (±211.0)
IgG (mg/dl) (SD)	2413.6 (±898.2)
IgM(mg/dl) (SD)	205.9 (±228.0)
Platelets (10 ⁴ /μl) (SD)	18.7 (±7.1)
ANA ≥ 1:40, n (%)	314 (87.2%)
ASMA ≥ 1:40, n (%)	118 (38.6%)
Cirrhosis, n (%)	49 (13.6%)
IAIHG score (SD)	16.3 (±3.1)
Definite AIH, n (%)	227 (63.1%)

AIH: autoimmune hepatitis, AST: aspartate aminotransferase, ALT: alanine aminotransferase, ALP: Alkaline Phosphatase, IgG: immunoglobulin G, IgM: immunoglobulin M, ANA: anti-nuclear antibody, ASMA: anti-smooth muscle antibody, IAIHG: International Autoimmune Hepatitis Group. Numbers or average values of each group are shown. Percentages or standard deviations are shown in parenthesis.

<https://doi.org/10.1371/journal.pone.0187325.t001>

HLA-DRB1 in type I AIH

To compare *HLA-DRB1* allele carrier frequency of the AIH patients and the healthy controls, we performed *HLA-DRB1* genotyping (Table 2). A significant association between type I AIH and *DRB1*04:05* ($P = 1.89 \times 10^{-21}$, corrected $P [P_c] = 5.86 \times 10^{-20}$, odds ratio [OR] 3.41, 95% confidence interval [CI] 2.65–4.38) was detected. *DRB1*04:01* was also associated with type I AIH ($P = 0.0006$, $P_c = 0.0193$, OR 2.97, 95%CI 1.62–5.43). On the contrary, *DRB1*13:02* was found to be protectively associated with type I AIH ($P = 0.0003$, $P_c = 0.0080$, OR 0.48, 95% CI 0.32–0.72). *HLA-DR4* serological group was associated with type I AIH ($P = 3.84 \times 10^{-18}$, OR 2.98, 95% CI 2.32–3.83), but *DR6* is protectively associated ($P = 2.10 \times 10^{-5}$, OR 0.54, 95% CI 0.41–0.72). Thus, *DRB1*04:05* and *DRB1*04:01* were predisposing and *DRB1*13:02* was protective for AIH.

*Demographic features of type I AIH patients with or without DRB1*04:05 or *13:02.*

Clinical features of AIH patients with or without *DRB1*04:05* or **13:02* were compared (Table 3). Serum levels of Immunoglobulin G (IgG), Immunoglobulin M (IgM), and IAIHG score were higher in AIH patients with *DRB1*04:05* than without. Positive rate of ASMA and the rate of definite AIH were higher in AIH patients with *DRB1*04:05* than without. The complication rate of cirrhosis tended to be higher in AIH patients with *DRB1*13:02* than without. Thus, specific clinical features of AIH patients possessing *DRB1*04:05* were observed.

HLA-DRB1 genotype in type I AIH

We investigated the genotype frequency in the AIH patients (Table 4). The homozygosity for *DRB1*04:05* (OR 2.79, 95% CI 1.45–5.38) did not confer higher OR for AIH than heterozygosity for *DRB1*04:05* (OR 3.10, 95% CI 2.40–4.00). In contrast, the homozygosity for *DRB1*13:02* (OR 0.15, 95% CI 0.01–2.56) conferred lower OR than heterozygosity for *DRB1*13:02* (OR 0.51, 95%

Table 2. HLA-DRB1 allele carrier frequency in the AIH patients and healthy controls.

	Case (n = 360)	Control (n = 1026)	P	OR	Pc	95%CI
DRB1*01:01	26 (7.2)	110 (10.7)	0.0634	0.65	NS	(0.42–1.01)
DRB1*03:01	1 (0.3)	3 (0.3)	1.0000	0.95	NS	(0.10–9.16)
DRB1*04:01	22 (6.1)	22 (2.1)	0.0006	2.97	0.0193	(1.62–5.43)
DRB1*04:03	15 (4.2)	47 (4.6)	0.8823	0.91	NS	(0.50–1.64)
DRB1*04:04	0 (0.0)	4 (0.4)	0.5780	0.32	NS	(0.02–5.87)
DRB1*04:05	185 (51.4)	243 (23.7)	1.89X10 ⁻²¹	3.41	5.68X10 ⁻²⁰	(2.65–4.38)
DRB1*04:06	15 (4.2)	76 (7.4)	0.0351	0.54	NS	(0.31–0.96)
DRB1*04:07	5 (1.4)	15 (1.5)	1.0000	0.95	NS	(0.34–2.63)
DRB1*04:10	12 (3.3)	32 (3.1)	0.8616	1.07	NS	(0.55–2.10)
DRB1*07:01	2 (0.6)	9 (0.9)	0.7382	0.63	NS	(0.14–2.94)
DRB1*08:02	35 (9.7)	72 (7.0)	0.1080	1.43	NS	(0.93–2.18)
DRB1*08:03	58 (16.1)	153 (14.9)	0.6091	1.10	NS	(0.79–1.52)
DRB1*08:09	0 (0.0)	2 (0.2)	1.0000	0.57	NS	(0.03–11.87)
DRB1*09:01	77 (21.4)	280 (27.3)	0.0298	0.72	0.8949	(0.54–0.97)
DRB1*10:01	5 (1.4)	5 (0.5)	0.1381	2.88	NS	(0.83–9.99)
DRB1*11:01	8 (2.2)	41 (4.0)	0.1361	0.55	NS	(0.25–1.18)
DRB1*12:01	25 (6.9)	75 (7.3)	0.9059	0.95	NS	(0.59–1.51)
DRB1*12:02	11 (3.1)	37 (3.6)	0.7384	0.84	NS	(0.43–1.67)
DRB1*13:01	2 (0.6)	8 (0.8)	1.0000	0.71	NS	(0.15–3.36)
DRB1*13:02	30 (8.3)	163 (15.9)	0.0003	0.48	0.0080	(0.32–0.72)
DRB1*14:02	1 (0.3)	0 (0.0)	0.2597	8.57	NS	(0.35–210.76)
DRB1*14:03	5 (1.4)	44 (4.3)	0.0078	0.31	0.2337	(0.12–0.80)
DRB1*14:04	0 (0.0)	4 (0.4)	0.5780	0.32	NS	(0.02–5.87)
DRB1*14:05	13 (3.6)	40 (3.9)	0.8744	0.92	NS	(0.49–1.75)
DRB1*14:06	5 (1.4)	29 (2.8)	0.1655	0.48	NS	(0.19–1.26)
DRB1*14:07	1 (0.3)	2 (0.2)	1.0000	1.43	NS	(0.13–15.78)
DRB1*14:54	20 (5.6)	58 (5.7)	1.0000	0.98	NS	(0.58–1.66)
DRB1*15:01	41 (11.4)	139 (13.5)	0.3171	0.82	NS	(0.57–1.19)
DRB1*15:02	62 (17.2)	224 (21.8)	0.0692	0.74	NS	(0.55–1.02)
DRB1*16:02	5 (1.4)	18 (1.8)	0.8119	0.79	NS	(0.29–2.14)
DR4	238 (66.1)	406 (39.6)	3.84X10 ⁻¹⁸	2.98		(2.32–3.83)
DR6 (*13, *14)	74 (20.6)	332 (32.4)	2.10X10 ⁻⁵	0.54		(0.41–0.72)
DR8	92 (25.6)	220 (21.4)	0.1234	1.26		(0.95–1.66)

AIH: autoimmune hepatitis, OR: odds ratio, CI: confidence interval, Pc: corrected P value, NS: not significant. Allele carrier frequencies are shown in parenthesis (%). Association was tested by Fisher’s exact test using 2x2 contingency tables under the dominant model.

<https://doi.org/10.1371/journal.pone.0187325.t002>

CI 0.34–0.78). The frequency of the DRB1*04:05*13:02 genotype was comparable. Of interest, higher frequencies of DRB1*04:05*08:02 ($P = 3.78 \times 10^{-6}$, OR 6.70, 95% CI 2.89–15.54) and DRB1*04:05*08:03 ($P = 9.80 \times 10^{-7}$, OR 4.54, 95% CI 2.47–8.35) genotypes in AIH were observed. Similarly, the DR4/DR8 genotype frequency in AIH was markedly increased ($P = 3.12 \times 10^{-9}$, OR 3.52, 95% CI 2.34–5.29). Thus, some specific heterozygous genotypes were predisposing for AIH.

Certain amino acid residues in HLA-DRβ chains were associated with AIH

The association with AIH with respect to each amino acid residue in the HLA-DRβ chain was analyzed. The amino acid residues of 11V, 13H, 33H, 57S, and 96Y in the DRβ chain showed

Table 3. Comparison of the demographics between AIH patients with or without *DRB1*04:05* or **13:02*.

	<i>DRB1*04:05(+)</i>	<i>DRB1*04:05(-)</i>	<i>P</i>	<i>DRB1*13:02(+)</i>	<i>DRB1*13:02(-)</i>	<i>P</i>
Number	185	175		30	330	
Male, n (%)	20 (10.8%)	23 (13.1%)	*0.5193	2 (6.7%)	41 (12.4%)	*0.5559
Age at onset, years (SD)	58.1 (±14.3)	59.2 (±14.7)	0.2897	59.5 (±15.8)	58.5 (±14.4)	0.6174
Mean age, years (SD)	63.2 (±12.2)	62.6 (±14.8)	0.6877	62.0 (±15.9)	63.0 (±13.3)	0.9408
Albumin (g/dl) (SD)	3.7 (±0.7)	3.8 (±0.9)	0.2699	3.7 (±0.6)	3.8 (±0.8)	0.2744
Total bilirubin (mg/dl) (SD)	3.6 (±4.6)	3.8 (±5.2)	0.8023	4.4 (±5.6)	3.6 (±4.9)	0.2202
AST(IU/L) (SD)	428.5 (±409.7)	513.2 (±659.0)	0.5735	498.4 (±498.4)	467.1 (±550.9)	0.7813
ALT(IU/L) (SD)	488.1 (±492.3)	525.1 (±529.0)	0.7793	549.4 (±562.2)	502.2 (±505.8)	0.8568
ALP(IU/L) (SD)	450.3 (±185.0)	478.4 (±237.1)	0.6656	463.8 (±217.1)	464.0 (±212.0)	0.9474
IgG (mg/dl) (SD)	2587.1 (±1005.7)	2119.8 (±840.8)	2.10X10 ⁻⁶	2242.9 (±878.5)	2370.6 (±964.3)	0.3771
IgM(mg/dl) (SD)	216.5 (±283.5)	144.1 (±126.2)	0.0020	140.3 (±125.5)	185.0 (±230.7)	0.1716
Platelets (104/μl) (SD)	18.5 (±7.1)	18.5 (±7.5)	0.9008	18.1 (±6.6)	18.5 (±7.4)	0.8625
ANA ≥ 1:40, n (%)	164 (88.6%)	150 (85.7%)	*0.4328	29 (96.7%)	285 (86.4%)	*0.1510
ASMA ≥ 1:40, n (%)	91 (55.2%)	27 (19.1%)	*6.46X10 ⁻¹¹	7 (33.3%)	111 (38.9%)	*0.6515
Cirrhosis, n (%)	26 (14.1%)	23 (13.1%)	*0.8782	8 (26.7%)	41 (12.4%)	*0.0462
IAIHG score (SD)	16.9 (3.1%)	15.6 (2.9%)	1.54X10 ⁻⁵	15.7 (2.9%)	16.3 (3.1%)	0.3476
Definite AIH, n (%)	133 (71.9%)	94 (53.7%)	*0.0005	17 (56.7%)	210 (63.6%)	*0.4383

Association was tested between AIH patients with or without *DRB1*04:05* or **13:02* by Fisher's exact test using 2x2 contingency tables or Mann-Whitney's U test.

*Fisher's exact test was employed.

<https://doi.org/10.1371/journal.pone.0187325.t003>

associations with AIH (Fig 1). Thus, this association analysis suggested roles for specific amino acid residues in the HLA-DRβ chain.

HLA-DQB1 in type I AIH

We next tried to compare *HLA-DQB1* allele carrier frequency of the AIH patients with 413 of the 1026 healthy controls, since previously reported genotyping results of *DQB1* were available for the 413 healthy controls[24]. When *DRB1* genotyping results for the 413 healthy controls were compared with those of the AIH patients, similar tendencies were observed (S1 and S2 Tables). *DQB1*04:01* allele was strongly associated with AIH ($P = 4.66 \times 10^{-18}$, $P_c = 6.99 \times 10^{-17}$, OR 3.89, 95% CI 2.84–5.33, S3 Table). We further examined *HLA-DQB1* genotype (S4 Table). The homozygosity for *DQB1*04:01* (OR 4.04, 95% CI 1.48–11.08) conferred comparative OR compared with heterozygosity for *DQB1*04:01* (OR 3.47, 95% CI 2.52–4.77). The higher frequency of *DQB1*04:01*06:01* genotype in AIH was observed ($P = 8.75 \times 10^{-6}$, OR 3.24, 95% CI 1.89–5.56). Thus, some of *DQB1* alleles or genotypes were predisposing for AIH.

DRB1-DQB1 haplotype in type I AIH

DRB1-DQB1 haplotype carrier frequencies were compared between the AIH patients and the 413 healthy controls (Table 5). Higher carrier frequencies of *DRB1*04:01-DQB1*03:01* ($P = 0.0007$, OR 4.42 95% CI 1.77–11.01) and *DRB1*04:05-DQB1*04:01* ($P = 1.99 \times 10^{-20}$, OR 4.32, 95% CI 3.14–5.96) were found in the AIH patients. *DRB1-DQB1* diplotype frequencies were also compared between the AIH patients and the 413 healthy controls (Table 5). The homozygosity for *DRB1*04:05-DQB1*04:01* (OR 5.07, 95% CI 1.69–15.20) conferred slightly higher OR for AIH than heterozygosity for *DRB1*04:05-DQB1*04:01* (OR 3.81, 95% CI 2.76–5.28). The diplotype frequencies of *DRB1*04:05-DQB1*04:01/DRB1*08:02-DQB1*03:02*

Table 4. HLA-DRB1 genotype frequency in the AIH patients and controls.

	Case (n = 360)	Control (n = 1026)	P	OR	95%CI
*04:05/not *04:05	167 (46.4)	224 (21.8)	5.72X10 ⁻¹⁸	3.10	(2.40–4.00)
*13:02/not *13:02	30 (8.3)	154 (15.0)	0.0011	0.51	(0.34–0.78)
*04:01/not *04:01	22 (6.1)	21 (2.0)	0.0003	3.11	(1.69–5.74)
*04:01/*04:05	4 (1.1)	1 (0.1)	0.0178	11.52	(1.28–103.39)
*04:05/*04:05	18 (5.0)	19 (1.9)	0.0035	2.79	(1.45–5.38)
*04:05/*08:02	18 (5.0)	8 (0.8)	3.78X10 ⁻⁶	6.70	(2.89–15.54)
*04:05/*08:03	27 (7.5)	18 (1.8)	9.80X10 ⁻⁷	4.54	(2.47–8.35)
*04:05/*13:02	8 (2.2)	25 (2.4)	1.0000	0.91	(0.41–2.04)
*13:02/*13:02	0 (0.0)	9 (0.9)	0.1225	0.15	(0.01–2.56)
DR4/DR4	34 (9.4)	57 (5.6)	0.0132	1.77	(1.14–2.76)
DR8/DR8	5 (1.4)	16 (1.6)	1.0000	0.89	(0.32–2.44)
DR6/DR6	3 (0.8)	25 (2.4)	0.0796	0.34	(0.10–1.12)
DR4/DR8	54 (15.0)	49 (4.8)	3.12X10 ⁻⁹	3.52	(2.34–5.29)
DR4/DR6	32 (8.9)	90 (8.8)	0.9144	1.01	(0.66–1.55)

AIH: autoimmune hepatitis, OR: odds ratio, 95%CI: confidence interval. Genotype frequencies are shown in parenthesis (%). Association was tested by Fisher's exact test using 2X2 contingency tables.

<https://doi.org/10.1371/journal.pone.0187325.t004>

($P = 0.0004$, OR 24.77, 95% CI 1.45–424.31) and *DRB1*04:05-DQB1*04:01/DRB1*08:03-DQB1*06:01* ($P = 1.18 \times 10^{-6}$, OR 10.64, 95% CI 3.19–35.46) were higher in AIH patients, suggesting the predisposing role of some specific heterozygous diplotypes in AIH.

Certain amino acid residues in HLA-DQβ chains were associated with AIH

The association with AIH with respect to each amino acid residue in the HLA-DQβ chain was analyzed in the comparison with the 413 healthy controls. The amino acid residues of 23L, 56L, 70E, and 71D in the DQβ chain showed associations with AIH (Fig 2). When each amino acid residue frequency in the DRβ chain for the 413 healthy controls was compared with that of the AIH patients, similar tendencies were observed (S1 Fig). Thus, this association analysis suggested roles for specific amino acid residues in the HLA-DQβ chains.

Discussion

Several studies have reported that type 1 AIH is associated with *HLA-DRB1*03:01* and *DRB1*04:01* in European [5] and *DRB1*04:05* in Japanese populations (Fig 3) [6,7,8]. In the present study, we showed an association of Japanese AIH with *DRB1*04:01* and **04:05*, indicating the common predisposing *DRB1*04:01* allele for AIH between European and Japanese populations. *DRB1*04:05* is also common predisposing allele for AIH between Latin America [13] and Japan. In previous studies, *DRB1*13:02* was protectively associated with type 1 AIH in Latin America [11,13,17]. We also confirmed a protective association of *DRB1*13:02* with Japanese AIH [8], but could not replicate the protective effects of *DRB1*15:01* [5,6]. These data indicated that the common protective *DRB1*13:02* allele for AIH between Latin America and Japan is also the protective allele shared by multiple autoimmune diseases [19].

Specific demographic features of Japanese AIH patients with *DRB1*04:05* were observed (Table 3). Elevated serum levels of IgG and IgM were detected in AIH patients with *DRB1*04:05*, as it was previously described [7]. In the present study, the IAIHG score, the positive rate of ASMA, and the rate of definite AIH were newly found to be higher in Japanese AIH patients




Fig 1. Associations of amino acid residues in DRβ chain with AIH. Each amino acid residue frequency in the HLA-DRβ chain for the 1026 healthy controls was compared with that of the AIH patients. Differences of amino acid residue carrier frequencies were analyzed by Fisher’s exact test using 2x2 contingency tables. Corrected *P* (*P_c*) values were calculated by multiplying the *P* value by the number of amino acid residues tested. Predisposing associations were indicated by filled circles and protective associations by open circles.

<https://doi.org/10.1371/journal.pone.0187325.g001>

with *DRB1*04:05*. Although *HLA* alleles are known to confer the risk for various autoimmune diseases, the precise mechanisms have not sufficiently been revealed. Thus, Japanese AIH patients with *DRB1*04:05* have typical clinical traits, probably because the auto-antigens

Table 5. *DRB1-DQB1* haplotype carrier or diplotype frequency in the AIH patients and controls.

<i>DRB1-DQB1</i> haplotype	Case (n = 360)	Control (n = 413)	<i>P</i>	OR	95%CI
*04:01-*03:01	22 (6.1)	6 (1.5)	0.0007	4.42	(1.77–11.01)
*04:05-*04:01	182 (50.6)	79 (19.1)	1.99X10 ⁻²⁰	4.32	(3.14–5.96)
*08:02-*03:02	21 (5.8)	21 (5.1)	0.7508	1.16	(0.62–2.15)
*08:02-*04:02	13 (3.6)	16 (3.9)	1.0000	0.93	(0.44–1.96)
*08:03-*03:01	3 (0.8)	2 (0.5)	0.6682	1.73	(0.29–10.39)
*08:03-*06:01	57 (15.8)	57 (13.8)	0.4768	1.17	(0.79–1.75)
*13:02-*06:04	31 (8.6)	49 (11.9)	0.1559	0.70	(0.44–1.12)
<i>DRB1-DQB1</i> diplotype					
*0405-*0401/not *04:05-*04:01	165 (45.8)	75 (18.2)	1.17X10 ⁻¹⁶	3.81	(2.76–5.28)
*04:05-*04:01/*04:01-*03:01	4 (1.1)	1 (0.2)	0.1898	4.63	(0.52–41.61)
*04:05-*04:01/*04:05-*04:01	17 (4.7)	4 (1.0)	0.0015	5.07	(1.69–15.20)
*04:05-*04:01/*08:02-*03:02	10 (2.8)	0 (0.0)	0.0004	24.77	(1.45–424.31)
*04:05-*04:01/*08:02-*04:02	7 (1.9)	3 (0.7)	0.2017	2.71	(0.70–10.56)
*04:05-*04:01/*08:03-*03:01	1 (0.3)	0 (0.0)	0.4657	3.45	(0.14–84.97)
*04:05-*04:01/*08:03-*06:01	26 (7.2)	3 (0.7)	1.18X10 ⁻⁶	10.64	(3.19–35.46)
*04:05-*04:01/*13:02-*06:04	8 (2.2)	8 (1.9)	0.8052	1.15	(0.43–3.10)

AIH: autoimmune hepatitis, OR: odds ratio, 95%CI: confidence interval. Genotype frequencies are shown in parenthesis (%). Association was tested by Fisher’s exact test using 2X2 contingency tables.

<https://doi.org/10.1371/journal.pone.0187325.t005>




Fig 2. Associations of amino acid residues in DQB1 chain with AIH. Each amino acid residue frequency in the HLA-DQB1 chain for the 413 healthy controls was compared with that of the AIH patients. Differences of amino acid residue carrier frequencies were analyzed by Fisher's exact test using 2x2 contingency tables. Corrected P (P_c) values were calculated by multiplying the P value by the number of amino acid residues tested. Predisposing associations were indicated by filled circles and protective associations by open circles.

<https://doi.org/10.1371/journal.pone.0187325.g002>

presented by DRB1*04:05 molecules would be important for development of the typical clinical traits of AIH.

It is well known that *DRB1*04:01* in European [26,27] and *DRB1*04:05* in Japanese populations [23,28] are associated with the susceptibility for rheumatoid arthritis (RA) and type 1 diabetes, in an analogous fashion to AIH. RA is a systemic autoimmune disease that affects synovial joints. RA-susceptible *DRB1* alleles shared a conserved amino acid sequence at position 70–74 (QKRAA, RRRRAA, or QRRAA) in HLA-DRβ chain and were designated as shared epitope alleles [23,26]. The shared epitope alleles include *DRB1*01:01*, **04:01*, **04:04*, **04:05*, **04:10*, **10:01*, **14:02*, and **14:06*. However, neither *DRB1*01:01* nor **04:10* seems to be a risk allele for AIH (Table 2). In the associations of *DRB1* alleles with susceptibility to RA, a gene dosage effect was reported; homozygosity for predisposing *DRB1* alleles confers higher OR than heterozygosity. However, we could not find any gene dosage effects of predisposing alleles or haplotypes in AIH. These data suggested the differential roles of *DRB1* in the pathogenesis between AIH and RA.

Type 1 diabetes is an autoimmune disease that affects pancreatic β cells producing insulin, resulting in the dysregulation of glucose metabolism. Susceptible *DRB1* alleles for type 1 diabetes are *DRB1*03:01*, **04:01*, **04:02*, **04:04*, **04:05*, and **08:01* and protective alleles are *DRB1*15:01*, **14:01*, and **07:01* in European populations [27]. In Japanese populations, *DRB1*04:05*, **08:02*, and **09:01* are predisposing alleles for type 1 diabetes and *DRB1*15:02* is a protective allele [28]. No gene dosage effect was observed for *DRB1*04:05*, though a gene dosage effect for *DRB1*09:01* was detected for type 1 diabetes. Similarly, we did not detect any gene dosage effects of the predisposing *DRB1*04:05* allele in AIH (Table 4). In addition, higher frequencies of the DR3/DR4, DR4/DR4, and DR4/DR8 genotypes in type 1 diabetes were reported [27]. In an analogous fashion, frequencies of the DR4/DR8 genotypes were higher in Japanese type 1 AIH (Table 4). Since the allele frequency of DR4 is higher than that of DR8 in Japanese populations, DR4 is a risk allele by itself, but DR8 is not, and type 1 AIH is a




Fig 3. Summary of the HLA-DRB1 alleles associated with type 1 AIH. The HLA-DRB1 alleles associated with type 1 AIH in European, Japanese, and Hispanic populations are illustrated. The underlined alleles are protective alleles.

<https://doi.org/10.1371/journal.pone.0187325.g003>

multifactorial disease, the DR4/DR8 genotype could not mainly contribute to the pathogenesis of type 1 AIH. It was also reported that the association of *DRB1*08* with the susceptibility of type 1 AIH was not detected in European populations [29], because of low frequency of *DRB1*08*. The DR4/DR8 heterozygous genotypes may cause an increased probability of self-antigen presentation, resulting in the increased risk of the diseases. Thus, the manner of *DRB1* association in type 1 AIH appears to be similar to that in type 1 diabetes.

Augmented frequencies of the DR3/DR4 and DR4/DR8 heterozygous genotypes in type 1 diabetes was explained by the pathologic importance of *trans*-complementing DQ α - β heterodimer molecules encoded by the *DQA1* allele of one haplotype and the *DQB1* allele of the other haplotype. The low stability of these molecules in *trans* was proposed to be causative to type 1 diabetes [27,30]. Analogously, DR4/DR8 heterozygous genotype was increased in Japanese type 1 AIH (Table 4), suggesting that *trans*-complementing DQ α - β heterodimer molecules might also play a role in AIH. *DRB1-DQB1* diplotype analysis revealed that *DRB1*04:05-DQB1*04:01/DRB1*08:02-DQB1*03:02* and *DRB1*04:05-DQB1*04:01/DRB1*08:03-DQB1*06:01* were significantly associated with AIH (Table 5). Japanese type 1 AIH was not significantly associated with *DRB1*08:02* or **08:03* (Table 2). Neither *DQB1*03:02* nor **06:01* was associated with type 1 AIH (S1 Table). Based on the conserved haplotype structure in the Japanese population, the *DQA1* allele in the haplotype of *DRB1*04:05-DQB1*04:01* is presumed to be *DQA1*03:03* [31] and the *DQA1* alleles in *DRB1*08:02-DQB1*03:02* and *DRB1*08:03-DQB1*06:01* are estimated to be *DQA1*03:01* and **01:03*, respectively. The high risk diplotype *DRB1*04:05-DQB1*04:01/DRB1*08:02-DQB1*03:02* is considered to encode *DQA1*03:03-DQB1*04:01* and *DQA1*03:01-DQB1*03:02* molecules in *cis* (DQ α - β heterodimer molecules formed by the protein products of *DQA1* and the *DQB1* alleles from the same chromosome) and *DQA1*03:03-DQB1*03:02* and *DQA1*03:01-DQB1*04:01* molecules in *trans* (DQ α - β heterodimer molecules formed by the protein products of *DQA1* and the *DQB1* alleles from the opposite chromosomes). The stabilities of these four types of DQ α - β heterodimer molecules were estimated to be low, according to the previous study [30]. The other high risk diplotype *DRB1*04:05-DQB1*04:01/DRB1*08:03-DQB1*06:01* is thought to encode *DQA1*03:03-DQB1*04:01* and *DQA1*01:03-DQB1*06:01* molecules in *cis* and *DQA1*03:03-DQB1*06:01* and *DQA1*01:03-DQB1*04:01* molecules in *trans*. The stabilities of these molecules except *DQA1*01:03-DQB1*06:01* in *cis* were also estimated to be low [30]. In patients with the risk diplotype *DRB1*04:05-DQB1*04:01/DRB1*08:03-DQB1*06:01*, the low stability of *trans*-complementing DQ α - β heterodimer molecules could explain the pathogenesis of type 1 AIH. In the case of type 1 diabetes, each of *DRB1*, *DQA1*, and *DQB1* is believed to have independent genetic contribution in the disease susceptibility based on the data from haplotype analysis [27]. Similar scenario might also apply to AIH. However, such analysis could not be performed in this study, because of the limited variety of *DRB1-DQB1* haplotypes in Japanese populations (Table 5). Furthermore, other culprit genes in linkage disequilibrium with *DRB1-DQB1* loci might be causative for AIH. Thus, the results of the association analyses of *DRB1* and *DQB1* in type 1 AIH could propose several lines of explanations on the mechanisms underlined in the pathogenesis.

We detected that amino acid residues of 11V, 13H, 33H, 57S, and 96Y in the HLA-DR β chain were associated with AIH (Fig 1A); these amino acids were encoded by *DRB1*04:05* allele. It was also found that some amino acid residues of the DQ β chains were associated with type 1 AIH (Fig 1B). These amino acid residues were also encoded by *DQB1*04:01*. These data were influenced by the strongest predisposing haplotype *DRB1*04:05-DQB1*04:01* for AIH, confirming the dominance of the *DRB1*04:05-DQB1*04:01* haplotype in type 1 AIH in Japanese populations.

In conclusion, we showed the predisposing association of *DRB1*04:01*, *DRB1*04:05*, and *DQB1*04:01* and the protective association of *DRB1*13:02* with Japanese type 1 AIH. The association of DR4/DR8 heterozygous genotype with AIH was newly noted. With respect to *DRB1-DQB1* haplotypes, *DRB1*04:01-DQB1*03:01* and *DRB1*04:05-DQB1*04:01* haplotypes were found to be associated with type 1 AIH. Of interest, the association of *DRB1*04:05-DQB1*04:01/DRB1*08:02-DQB1*03:02* and *DRB1*04:05-DQB1*04:01/DRB1*08:03-DQB1*06:01* diplotypes was revealed. These data suggested the roles of specific combinations of *DRB1* and *DQB1* alleles or haplotypes in the pathogenesis of type 1 AIH. Further large scale studies

should be performed to confirm these findings. In addition, because the *HLA* allele distribution pattern is different in other ethnic populations, it would be intriguing and informative to analyze *DRB1* and *DQB1* alleles in type 1 AIH in other populations.

Supporting information

S1 Fig. Associations of amino acid residues in DR β chain with AIH.

(PDF)

S1 Table. *HLA-DRB1* allele carrier frequency in the AIH patients and the 413 healthy controls.

(PDF)

S2 Table. *HLA-DRB1* genotype frequency in the AIH patients and the 413 healthy controls.

(PDF)

S3 Table. *HLA-DQB1* allele carrier frequency in the AIH patients and the 413 healthy controls.

(PDF)

S4 Table. *HLA-DQB1* genotype frequency in the AIH patients and the 413 healthy controls.

(PDF)

Acknowledgments

The members of the NHO-AIH study group are: Kiyoshi Migita (Fukushima Medical University School of Medicine), Minoru Nakamura (Nagasaki University Graduate School of Biomedical Sciences), Hideo Nishimura (NHO Asahikawa Medical Center), Hironori Sakai (NHO Beppu Medical Center), Eiichi Takezaki (NHO Higashi Hiroshima Medical Center), Noboru Hirashima, Hironao Takahashi (NHO Higashi Nagoya National Hospital), Noriaki Naeshiro (NHO Higashihiroshima Medical Center), Yukio Oohara (NHO Hokkaido Medical Center), Hajime Ohta (NHO Kanazawa Medical Center), Takeaki Sato (NHO Kokura Medical Center), Kazuhiro Sugi (NHO Kumamoto Medical Center), Hiroshi Kouno (NHO Kure Medical Center), Motoyuki Kohjima, Makoto Nakamura (NHO Kyushu Medical Center), Michio Kato, Iwao Yabuuchi (NHO Minami Wakayama Medical Center), Seigo Abiru, Sung Kwan Bae, Shigemune Bekki, Satoru Hashimoto, Hiromi Ishibashi, Yuka Jiuchi, Atsumasa Komori, Shinya Nagaoka, Masashi Ohtani, Katsumi Yamasaki, Hiroshi Yatsuhashi (NHO Nagasaki Medical Center), Masaaki Shimada (NHO Nagoya Medical Center), Fujio Makita (NHO Nishigunma National Hospital), Toyokichi Muro (NHO Oita Medical Center), Haruhiro Yamashita (NHO Okayama Medical Center), Eiji Mita (NHO Osaka Medical Center), Taizo Hijioka (NHO Osaka Minami Medical Center), Eiji Mita (NHO Osaka National Hospital), Yoko Nakamura, Yukio Watanabe (NHO Sagamihara National Hospital), Minoru Tomizawa (NHO Shimoshizu National Hospital), Kaname Yoshizawa (NHO Shinshu Ueda Medical Center), Atsushi Naganuma (NHO Takasaki General Medical Center), Masahiro Kikuchi (NHO Tokyo Medical Center), Hiroshi Kamitsukasa, Michiyasu Yagura (NHO Tokyo National Hospital), Keisuke Ario (NHO Ureshino Medical Center), Tatsuji Komatsu (NHO Yokohama Medical Center), Michio Yasunami (Saga-ken Medical Centre Koseikan, Life Science Institute), and Hiroshi Furukawa (University of Tsukuba, Faculty of Medicine).

Author Contributions

Conceptualization: Hiroshi Furukawa, Michio Yasunami, Aya Kawasaki, Atsushi Takahashi, Kazumichi Abe, Hiromasa Ohira, Naoyuki Tsuchiya, Kiyoshi Migita.

Data curation: Hiroshi Furukawa.

Formal analysis: Shomi Oka, Hiroshi Furukawa.

Funding acquisition: Michio Yasunami, Kiyoshi Migita.

Investigation: Shomi Oka, Hiroshi Furukawa, Michio Yasunami, Hitomi Nakamura.

Project administration: Kiyoshi Migita.

Resources: Minoru Nakamura, Atsumasa Komori, Seigo Abiru, Shinya Nagaoka, Satoru Hashimoto, Atsushi Naganuma, Noriaki Naeshiro, Kaname Yoshizawa, Haruhiro Yamashita, Keisuke Ario, Hajime Ohta, Hironori Sakai, Iwao Yabuuchi, Hiroshi Yatsuhashi, Shigetoh Tohma, Kiyoshi Migita.

Supervision: Michio Yasunami, Hiromasa Ohira, Naoyuki Tsuchiya, Kiyoshi Migita.

Writing – original draft: Shomi Oka.

Writing – review & editing: Hiroshi Furukawa, Aya Kawasaki, Hiromasa Ohira, Naoyuki Tsuchiya, Kiyoshi Migita.

References

1. Manns MP, Vogel A. Autoimmune hepatitis, from mechanisms to therapy. *Hepatology*. 2006; 43(2 Suppl 1):S132–44. <https://doi.org/10.1002/hep.21059> PMID: 16447290.
2. Krawitt EL. Autoimmune hepatitis. *N Engl J Med*. 2006; 354(1):54–66. <https://doi.org/10.1056/NEJMra050408> PMID: 16394302.
3. Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. *Gastroenterology*. 2010; 139(1):58–72 e4. <https://doi.org/10.1053/j.gastro.2010.04.053> PMID: 20451521.
4. de Boer YS, van Gerven NM, Zwieters A, Verwer BJ, van Hoek B, van Erpecum KJ, et al. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. *Gastroenterology*. 2014; 147(2):443–52 e5. <https://doi.org/10.1053/j.gastro.2014.04.022> PMID: 24768677.
5. Strettell MD, Donaldson PT, Thomson LJ, Santrach PJ, Moore SB, Czaja AJ, et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. *Gastroenterology*. 1997; 112(6):2028–35. PMID: 9178696.
6. Umemura T, Katsuyama Y, Yoshizawa K, Kimura T, Joshita S, Komatsu M, et al. Human leukocyte antigen class II haplotypes affect clinical characteristics and progression of type 1 autoimmune hepatitis in Japan. *PLoS One*. 2014; 9(6):e100565. <https://doi.org/10.1371/journal.pone.0100565> PMID: 24956105.
7. Furumoto Y, Asano T, Sugita T, Abe H, Chuganji Y, Fujiki K, et al. Evaluation of the role of HLA-DR antigens in Japanese type 1 autoimmune hepatitis. *BMC Gastroenterol*. 2015; 15(144):144. <https://doi.org/10.1186/s12876-015-0360-9> PMID: 26489422.
8. Maeda Y, Migita K, Higuchi O, Mukaino A, Furukawa H, Komori A, et al. Association between Anti-Ganglionic Nicotinic Acetylcholine Receptor (gAChR) Antibodies and HLA-DRB1 Alleles in the Japanese Population. *PLoS One*. 2016; 11(1):e0146048. <https://doi.org/10.1371/journal.pone.0146048> PMID: 26807576.
9. Lim YS, Oh HB, Choi SE, Kwon OJ, Heo YS, Lee HC, et al. Susceptibility to type 1 autoimmune hepatitis is associated with shared amino acid sequences at positions 70–74 of the HLA-DRB1 molecule. *J Hepatol*. 2008; 48(1):133–9. <https://doi.org/10.1016/j.jhep.2007.08.019> PMID: 18022727.
10. Vazquez-Garcia MN, Alaez C, Olivo A, Debaz H, Perez-Luque E, Burguete A, et al. MHC class II sequences of susceptibility and protection in Mexicans with autoimmune hepatitis. *J Hepatol*. 1998; 28(6):985–90. PMID: 9672174.
11. Goldberg AC, Bittencourt PL, Mouglin B, Cancado EL, Porta G, Carrilho F, et al. Analysis of HLA haplotypes in autoimmune hepatitis type 1: identifying the major susceptibility locus. *Hum Immunol*. 2001; 62(2):165–9. PMID: 11182227.

12. Fortes Mdel P, Machado IV, Gil G, Fernandez-Mestre M, Dagher L, Leon RV, et al. Genetic contribution of major histocompatibility complex class II region to type 1 autoimmune hepatitis susceptibility in Venezuela. *Liver Int.* 2007; 27(10):1409–16. <https://doi.org/10.1111/j.1478-3231.2007.01581.x> PMID: 17927716.
13. Duarte-Rey C, Pardo AL, Rodriguez-Velosa Y, Mantilla RD, Anaya JM, Rojas-Villarraga A. HLA class II association with autoimmune hepatitis in Latin America: a meta-analysis. *Autoimmun Rev.* 2009; 8(4):325–31. <https://doi.org/10.1016/j.autrev.2008.11.005> PMID: 19041429.
14. Kaur N, Minz RW, Anand S, Saikia B, Aggarwal R, Das A, et al. HLA DRB1 Alleles Discriminate the Manifestation of Autoimmune Hepatitis as Type 1 or Type 2 in North Indian Population. *J Clin Exp Hepatol.* 2014; 4(1):14–8. <https://doi.org/10.1016/j.jceh.2013.12.002> PMID: 25755530.
15. Baharlou R, Faghihi-Kashani A, Faraji F, Najafi-Samei M, Setareh M, Zamani F, et al. HLA-DRB1 alleles of susceptibility and protection in Iranians with autoimmune hepatitis. *Hum Immunol.* 2016; 77(4):330–5. <https://doi.org/10.1016/j.humimm.2016.01.007> PMID: 26780502.
16. Hassan N, Siddiqui AR, Abbas Z, Hassan SM, Soomro GB, Mubarak M, et al. Clinical Profile and HLA Typing of Autoimmune Hepatitis From Pakistan. *Hepat Mon.* 2013; 13(12):e13598. <https://doi.org/10.5812/hepatmon.13598> PMID: 24358040.
17. Pando M, Larriba J, Fernandez GC, Fainboim H, Ciocca M, Ramonet M, et al. Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. *Hepatology.* 1999; 30(6):1374–80. <https://doi.org/10.1002/hep.510300611> PMID: 10573514.
18. Yoshizawa K, Ota M, Katsuyama Y, Ichijo T, Matsumoto A, Tanaka E, et al. Genetic analysis of the HLA region of Japanese patients with type 1 autoimmune hepatitis. *J Hepatol.* 2005; 42(4):578–84. <https://doi.org/10.1016/j.jhep.2004.12.019> PMID: 15763345.
19. Furukawa H, Oka S, Tsuchiya N, Shimada K, Hashimoto A, Tohma S, et al. The role of common protective alleles HLA-DRB1*13 among systemic autoimmune diseases. *Genes Immun.* 2017; 2017(in press). <https://doi.org/10.1038/gene.2016.40> PMID: 27829665.
20. Koning F, Thomas R, Rossjohn J, Toes RE. Coeliac disease and rheumatoid arthritis: similar mechanisms, different antigens. *Nat Rev Rheumatol.* 2015; 11(8):450–61. <https://doi.org/10.1038/nrrheum.2015.59> PMID: 25986717.
21. Migita K, Watanabe Y, Jiuchi Y, Nakamura Y, Saito A, Yagura M, et al. Hepatocellular carcinoma and survival in patients with autoimmune hepatitis (Japanese National Hospital Organization-autoimmune hepatitis prospective study). *Liver Int.* 2012; 32(5):837–44. <https://doi.org/10.1111/j.1478-3231.2011.02734.x> PMID: 22221966.
22. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. *J Hepatol.* 1999; 31(5):929–38. PMID: 10580593.
23. Oka S, Furukawa H, Kawasaki A, Shimada K, Sugii S, Hashimoto A, et al. Protective effect of the *HLA-DRB1*13:02* allele in Japanese rheumatoid arthritis patients. *PLoS One.* 2014; 9(6):e99453. <https://doi.org/10.1371/journal.pone.0099453> PMID: 24911054
24. Furukawa H, Oka S, Kawasaki A, Shimada K, Sugii S, Matsushita T, et al. Human Leukocyte Antigen and Systemic Sclerosis in Japanese: The Sign of the Four Independent Protective Alleles, DRB1*13:02, DRB1*14:06, DQB1*03:01, and DPB1*02:01. *PLoS One.* 2016; 11(4):e0154255. <https://doi.org/10.1371/journal.pone.0154255> PMID: 27116456.
25. Kamatani N, Kawamoto M, Kitamura Y, Harigai M, Okumoto T, Sumino Y. Establishment of B-cell lines derived from 996 Japanese individuals. *Tissue Culture Res Commun.* 2004; 23(2):71–80.
26. Reveille JD. The genetic contribution to the pathogenesis of rheumatoid arthritis. *Curr Opin Rheumatol.* 1998; 10(3):187–200. PMID: 9608321
27. Erlich H, Valdes AM, Noble J, Carlson JA, Varney M, Concannon P, et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. *Diabetes.* 2008; 57(4):1084–92. <https://doi.org/10.2337/db07-1331> PMID: 18252895.
28. Kawabata Y, Ikegami H, Kawaguchi Y, Fujisawa T, Shintani M, Ono M, et al. Asian-specific HLA haplotypes reveal heterogeneity of the contribution of HLA-DR and -DQ haplotypes to susceptibility to type 1 diabetes. *Diabetes.* 2002; 51(2):545–51. PMID: 11812768.
29. Miyadera H, Ohashi J, Lernmark A, Kitamura T, Tokunaga K. Cell-surface MHC density profiling reveals instability of autoimmunity-associated HLA. *J Clin Invest.* 2015; 125(1):275–91. <https://doi.org/10.1172/JCI74961> PMID: 25485681.
30. Nakajima F, Nakamura J, Yokota T. Analysis of HLA haplotypes in Japanese, using high resolution allele typing. *MHC.* 2001; 8(1):1–32.